| 替加环素联合头孢哌酮舒巴坦治疗ICU重度腹腔感染的效果 |
| |
| 引用本文： | 杜江涛,李扬,欧阳山丹,刘炳震,林珍.替加环素联合头孢哌酮舒巴坦治疗ICU重度腹腔感染的效果[J].国际医药卫生导报,2022,28(21):3077-3081. |
| |
| 作者姓名： | 杜江涛 李扬 欧阳山丹 刘炳震 林珍 |
| |
| 作者单位： | 中国人民解放军陆军第七十三集团军医院药剂科，厦门 361000 |
| |
| 摘 要： | 目的 探讨替加环素联合头孢哌酮舒巴坦治疗重症监护病房（ICU）重度腹腔感染对血浆基质金属蛋白酶-9（MMP-9）、免疫功能、炎性指标的影响。方法 选择2016年4月至2021年4月期间中国人民解放军陆军第七十三集团军医院重症医学科收治的ICU重度腹腔感染80例作为研究资料，男46例，女34例，年龄（61.57±4.08）岁，简单随机分为对照组和观察组各40例，分别采取头孢哌酮舒巴坦与替加环素联合头孢哌酮舒巴坦治疗，比较两组治疗效果及不良反应发生情况，统计学方法采用χ2检验、t检验。结果 观察组治疗有效率为92.50%（37/40），高于对照组［75.00%（30/40）］，差异有统计学意义（χ2=4.500，P<0.05）。治疗后，两组MMP-9、Toll样受体（TLR-4）、Ⅳ型胶原（Ⅳ-C）水平减少，与治疗前有明显变化，观察组3项指标水平较对照组更少，差异均有统计学意义（t=8.886、9.097、10.124，均P<0.05）。治疗后，两组C-反应蛋白（CRP）、降钙素原（PCT）、白介素-6（IL-6）水平有所减少，与治疗前比较的变化明显，对照组在3项指标水平方面与观察组相比更高，差异均有统计学意义（t=7.858、3.807、5.396，均P<0.05）。治疗后，两组T亚群细胞CD3+、CD4+、CD4+/CD8+水平有所增加，较治疗前的指标水平有明显变化，对照组的3项指标水平较观察组更少，差异均有统计学意义（t=3.326、5.062、4.682，均P<0.05）。用药治疗过程中，共有9例病患出现不良反应，其中有4例来自对照组，剩余5例来自观察组，差异无统计学意义（P>0.05）。结论 ICU重度腹腔感染患者采取替加环素联合头孢哌酮舒巴坦治疗可有效缓解症状，改善机体健康状况，并降低血浆MMP-9、TLR-4、Ⅳ-C表达，降低炎症因子水平，减轻炎性反应，改善免疫功能，取得确切的疗效，联合用药不会明显增加不良反应，但需加强监测，值得推广应用。
|
| 关 键 词： | 替加环素 头孢哌酮舒巴坦 腹腔感染 治疗效果 免疫功能 炎症因子 |
| 收稿时间： | 2022-01-12 |
Effect of tigecycline combined with cefoperazone-sulbactam in treatment
of severe intra-abdominal infection in ICU |
| |
| Du Jiangtao,Li Yang,Ouyang Shandan,Liu Bingzhen,Lin Zhen.Effect of tigecycline combined with cefoperazone-sulbactam in treatment
of severe intra-abdominal infection in ICU[J].International Medicine & Health Guidance News,2022,28(21):3077-3081. |
| |
| Authors: | Du Jiangtao Li Yang Ouyang Shandan Liu Bingzhen Lin Zhen |
| |
| Affiliation: | Department of Pharmacy, Hospital of 73rd Group, China's People's
Liberation Army, Xiamen 361000, China |
| |
| Abstract: | Objective To investigate the effect of tigecycline combined with
cefoperazone-sulbactam on plasma matrix metalloproteinase-9 (MMP-9), immune
function, and inflammatory indicators in patients with severe intra-abdominal
infection in ICU. Methods Eighty cases of severe
abdominal infection in ICU admitted to Intensive Care Department, Hospital of
73rd Group, China's People's Liberation Army from April 2016 to April 2021 were
seledted as the research data, including 46 males and 34 females who were
(61.57±4.08) years old, and were randomly divided into a control group and an
observation group by lottery, with 40 cases in each group. The control group
were treated with cefoperazone-sulbactam, and the observation group with
tigecycline and cefoperazone-sulbactam. The therapeutic effects and incidences
of adverse reactions of the two groups were compared. χ2 and t tests
were applied. Results The effective rate
was 92.50% (37/40) in the observation group, and was 75.00% (30/40) in the
control group, with a statistical difference (χ2=4.500, P<0.05).
After the treatment, the levels of MMP-9, Toll-like receptors-4 (TLR-4), and
collagen type Ⅳ (Ⅳ-C) were lower than those before the treatment
in both groups, and were lower in the observation group than in the control
group, with statistical differences (t=8.886,
9.097, and 10.124; all P<0.05).
After the treatment, the levels of C-reactive protein (CRP), procalcitonin
(PCT), and interleukin-6 (IL-6) were lower than those before the treatment in
both groups, and were lower in the observation group than in the control group,
with statistical differences (t=7.858,
3.807, and 5.396; all P<0.05).
After the treatment, the levels of CD3+ and CD4+ and CD4+/CD8+ increased in
both groups, and were higher in the observation group than in the control
group, with statistical differences (t=3.326,
5.062, and 4.682; all P<0.05).
During the treatment, 9 patients had adverse reactions, including 4 in the
control group and 5 in the observation group, with no statistical difference (P>0.05). Conclusions Tigecycline combined with cefoperazone-sulbactam for ICU patients with
severe intra-abdominal infection can effectively relieve their symptoms,
improve their health and immune function, and reduce the levels of plasma
MMP-9, TLR-4, Ⅳ-C, and inflammatory
factors and inflammatory response, and achieve definite curative effect.
Combination medication does not significantly increase adverse reactions, but
it needs to strengthen monitoring. It is worth being generalized. |
| |
| Keywords: | Tigecycline Cefoperazone-sulbactam Abdominal infection Therapeutic effect Immune function Inflammatory factors |
|
| 点击此处可从《国际医药卫生导报》浏览原始摘要信息 |
|
点击此处可从《国际医药卫生导报》下载全文 |
|
